Indoco Remedies posted a 7.4% rise in Q2 FY27 consolidated revenue to Rs 506.9 crore, marking a key milestone despite geopolitical pressures. While international formulations saw robust 12.1% growth, domestic acute therapies faced headwinds from a weak monsoon. The company reported a Rs 13 crore impact from elevated freight costs but highlighted successful regulatory audits and ongoing debt reduction as key strategic positives for shareholders.
Indoco Remedies Q2 FY27 Revenue Hits Rs 506.9 Crore
Revenue grew 7.4% YoY to Rs 506.9 crore; EBITDA rose 7.6% to Rs 46.4 crore.
Reader Takeaway: Strong international expansion in regulated markets drives growth, while high freight costs and weak domestic seasonality squeeze margins.
What just happened
Indoco Remedies crossed the Rs 500 crore quarterly revenue milestone in Q2 FY27. Despite the revenue growth, the company faced significant margin pressure, absorbing a Rs 13 crore hit due to rising freight and material costs caused by geopolitical conflicts. EBITDA stood at Rs 46.4 crore with a margin of 9.2%.
Why this matters
The company is successfully scaling its international footprint, with regulated markets in the US and Europe growing by 21.1% and 23.5%, respectively. This performance highlights the company's ability to navigate global supply chain challenges. Additionally, the successful completion of MHRA and ANVISA audits reinforces its operational quality.
The backstory
Domestic formulations, historically a key driver, faced a slowdown this quarter, with revenue dipping to Rs 212.8 crore compared to Rs 226.1 crore in the year-ago period. Management attributed this to an absent monsoon that reduced the demand for seasonal acute therapies.
What changes now
Indoco Remedies is evaluating a potential restructuring to separate its OTC (Warren Remedies) and API businesses. A new subsidiary, Warren Life Sciences, has been incorporated to support this goal. The company also prioritized debt reduction, repaying Rs 50-65 crore in H1 FY27, and has committed to keeping capital expenditure to a minimum for the near term.
Risks to watch
The primary short-term risk remains the volatility in freight and input costs, which are currently eroding margins. Investors should also watch for the speed at which domestic growth recovers from its recent seasonal slump.
What to track next
Watch for updates on the formal separation of the API and OTC businesses, as well as management's guidance on when gross margins might return to the 68-70% range as global logistics costs normalize.